Authored by Vincent Rajkumar, published on 2026-04-17 07:47:36.0
Updated 2025 treatment algorithm for multiple myeloma patients with first relapse. Based on recent data presented at ASH 2025 about the MajesTEC-3 trial which showed higher PFS for patients using the tec-dara combination.Consider salvage ASCT as alternative in patients eligible for ASCT who have not had transplant before; Consider 2°d auto SCT if eligible and had >36 months response duration with maintenance to first ASCT
Not Refractory to Anti-CD38
Unable to give cell therapy and bispecifics per guidelines
Standard Triplet**
Have access, and able to give cell therapy and bispecific per recommended guidelines
Cilta-cel* or Tec-Dara
Refractory to Anti-CD38
Have access, and able to give cell therapy per recommended guidelines